Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT027 in Recurrent or Progressive Glioblastoma
NCT07386002Phase 2Not yet recruiting
- Sponsor
- Suzhou Maximum Bio-tech
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of MT027 CAR-T cells in glioblastoma (GBM), sponsored by Suzhou Maximum Bio-tech. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
MT027 CAR-T cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07386002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07386002.